Mizuho Securities analyst Ann Hynes maintains $CVS Health (CVS.US)$ with a buy rating, and sets the target price at $66.
According to TipRanks data, the analyst has a success rate of 59.6% and a total average return of 9.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $CVS Health (CVS.US)$'s main analysts recently are as follows:
The firm has adjusted its future earnings expectations for CVS Health downward and is evaluating the potential trajectory for recovery.
The analyst anticipates that CVS Health's medical loss ratio trends will likely see improvement by 2025 due to start payments. However, it is expected that the MLR will continue to be higher than the 2023 baselines.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
